|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors with a long-term horizong may find it valuable to assess Exactech Inc’s (NASDAQ:EXAC) earnings trend over time and against its industry benchmark as opposed to simply looking at aRead More...
Moody's Investors Service, ("Moody's") assigned a B2 Corporate Family Rating and a B2-PD Probability of Default Rating to Osteon Merger Sub, Inc. ("Osteon"). Moody's also assigned a ...
Medical device maker Exactech Inc said on Monday TPG Capital raised its offer to buy the company to $737 million cash and its board agreed to the amended terms, saying the offer was in the best interests of shareholders. Exactech expects the deal to close during the first quarter of 2018. By going private, Exactech would escape the quarter-to-quarter scrutiny of the public markets.
** Medical device maker Exactech Inc said TPG Capital raised its offer to buy the company to $737 million cash and its board agreed to the amended terms, saying the offer was in the best interests of shareholders. ** Insurer Hartford Financial Services Group said it would sell its Talcott Resolution unit in a deal valued at $2.05 billion, completing its exit from the life and annuity business.
On a per-share basis, the Gainsville, Florida-based company said it had net income of 20 cents. The maker of bone and joint restoration products posted revenue of $61.4 million in the period. Exactech ...
Exactech Inc (NASDAQ:EXAC)’s predicted earnings growth next year is expected to be a gigantic one, coming in over 150%. With the recent EPS being $0.055, expected growth will push theRead More...
Categories: Yahoo FinanceGet free summary analysis Exactech, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 67.33 million, Net Earnings of USD 4.83 million. Gross margins narrowed from 62.68% to 61.70% compared to the same period last year, operating (EBITDA) margins now 17.38% from 17.16%. Change in operating cash ... Read more (Read more...)
Exactech (EXAC) has been leveraging on its Knee business. The Truliant Knee System is a notable platform in the Knee space, which offers an advanced approach to total knee replacement surgeries.
On a per-share basis, the Gainsville, Florida-based company said it had net income of 33 cents. The maker of bone and joint restoration products posted revenue of $67.3 million in the period. For the current ...
Exactech, Inc.(EXAC) took a step towards it's goal of providing an all-inclusive range of knee replacement systems with the launch of ExactechGPS TKA PLUS.